何以丰  教授  Yifeng He, Associate Professor

发表时间:2024-05-22 16:49
文章附图

Yifeng He, MD and PhD.

The deputy director of Lab of Obstetrics and Gynecology at Pudong Medical Center (PMC) of Fudan University and a chief doctor of Obstetrics and Gynecology at Fudan PMC. An associate Professor of Department of Obstetrics and Gynecology at Renji Hospital, School of Medicine, Shanghai Jiaotong University. A PI of Shanghai Key Lab of Gynecological Oncology and a chief doctor of Obstetrics and Gynecology at Renji Hospital, School of Medicine, Shanghai Jiaotong University. The Vice Chairman of the Youth Work Committee of Shanghai Genetic Society. Dr. He got his Doctoral degree in Medicine (MD) at School of Medicine, Fudan University in 1999, Master degree in Science (MS) at Institute of Genetics, Fudan University in 2002, and PhD in Medicine at School of Medicine, Fudan University in 2011. Dr. He completed two-year post-Doc training at Department of Obstetrics and Gynecology, University of Pennsylvania, USA during 2015-2017.

Dr. He has been actively engaged in clinical and basic researches in Oncology, Stem Cells, and Molecular Genetics related to Obstetrics and Gynecology for more than 20 years. Dr. He is the inventor of the first paten for the detection of multiple genotypes (>100 genotypes) of human papilloma virus (HPV) by PCR, the first patent for the detection of integrated HPV by PCR and the first patent for molecular pathological staratification of cervical neoplasia.In china Dr. He is also the first expert who discovered the three basic principles in Developmental Biology. Dr. He also developed theories in Computational Developmental Biology and Biocybernetics. Dr. He got a lot of prizes for his achievements, including a Morning Star Award for Young Scientists and Technologists in Shanghai (2010), a First-level A ward for Industry-University-Institute Cooperation in Shanghai (2022).

Research Interests

1.Invitro detection of HPV infection and risk-stratification of cervical precancerous diseases.

2.Early detection of endometrial cancer and molecular classification of endometrial hyperplasia, neoplasia and carcinoma.

3.Early detection of ovarian cancer and immune, cell and gene therapy (CAR-T andCAR-NK) of late-stage ovarian cancer.

4.Identification and prevent of Hereditary Breast and Ovarian Cancer Syndrome(HBOC) and Lynch Syndrome.

5.Utility and theories of stem cells, including umbilical cord blood (UCB)/stem cells, inducible pluripotent stem cells (iPS) and fertilized egg.

Publications

1.He Y, Shi J, Zhao H, Wang Y, Zhang C, Han S, He Q, Li X, Li S, Wang W, Yi M, Hu X, Xing Z, Han H, Gao Y, Zhou Q, Lu L, Guo J, Cao H, Lu C, Hou Y, Chen D, Yang F, Lei P, Di W, Qian J, Xia Y, Zhang Y, Deng Y, Zhu J, Xu C. p16INK4A flow cytometry of exfoliated cervical cells: Its role in quantitative pathology and clinical diagnosis of squamous intraepithelial lesions. Clin Transl Med. 2023 Mar;13(3):e1209.

2.He Y, Gu Z, Zhu Q, Chen M, He C, Huang Y, Li Q, Di W. CA125 over-release behavior following a 75-g oral glucose test as a predictive biomarker of multidrug resistance in patients with ovarian cancer. Int J Cancer. 2019 Sep 15;145(6):1690-1700

3.Gu ZW, He YF, Wang WJ, Tian Q, Di W. MiR-1180 from bone marrow-derived mesenchymal stem cells induces glycolysis and chemoresistance in ovarian cancer cells by upregulating the Wnt signaling pathway. J Zhejiang Univ Sci B. 2019 Mar.;20(3):219-237.

4.Gu Z, He Y, Zhang Y, Chen M, Song K, Huang Y, Li Q, Di W. Postprandial increase inserum CA125 as a surrogate biomarker for early diagnosis of ovarian cancer. J Transl Med. 2018 May 1;16(1):114.

5.He Y, Zhu Q, Chen M, Huang Q, Wang W, Li Q, Huang Y, Di W. The changing 50%inhibitory concentration (IC50) of cisplatin: a pilot study on the artifacts ofthe MTT assay and the precise measurement of density-dependent chemoresistancein ovarian cancer. Oncotarget. 2016 Oct 25;7(43):70803-70821.

6.He Y, Zhang R, Chen M, Chen C, Zhu Q, Lu H, Wei Z, Li F, Zhang X, Xu C, Yu L.Diagnosis of 25 genotypes of human papillomaviruses for their physical statusesin cervical precancerous/cancerous lesions: a comparison of E2/E6E7 ratio-basedvs. multiple E1-L1/E6E7 ratio-based detection techniques. J Transl Med 2014;12: 282

7.He Y, Wu X, Zhu Q, Wu X, Feng L, Wu X, Zhao A, Di W. Combined laparoscopy and hysteroscopy vs. uterine curettage in the uterine artery embolization-based management of cesarean scar pregnancy: a retrospective cohort study. BMC Womens Health 2014; 14: 116. (IF=1.7)

8.He Y, Zhang M, Sun X, Li Q, Wang W, Zhao A, Di W. A high M1/M2 ratio oftumor-associated macrophages is associated with extended survival in ovarian cancer patients, J Ovarian Res 2014, 7: 19

9.H Y, Zhang M, Wu X, Sun X, Xu T, He Q, Di W. High MUC2 expression in ovarian canceris inversely associated with the M1/M2 ratio of tumor-associated macrophages and patient survival time. Plos One, 2013, 8(12): e79769

10.He Y, Zhang R, Zhang X, Xing B, Sheng Y, Lu H, Wei Z. Estrogen receptor-regulated microRNAs contribute to the BCL2/BAX imbalance in endometrial adenocarcinoma and precancerous lesions. Cancer Lett. 2012 Jan 28;314(2):155-65.

Lab and Industry Opportunities:

Dr. He’s lab is now recruiting for 1-3 interns from the MSc program in Precision Medicine of NUS (National University of Singapore), who can assist indeveloping in vitro diagnostic devices (IVD) for early detection of Gynecological Cancers or building CAR-T and CAR-NK for Gynecological disorders(malignancies or benign diseases).

Salary/Stipend:2000-5000 RMB/month.

Contact Us: bjsun@ghlget.cn




复旦临港产业创新平台
------------------————————————————————————————————————————————————————————————————
联 系 方 式
地址:上海市浦东新区南汇新城镇海洋四路99弄6号楼
联系电话:021-58162556
邮编:201306


快 速 链 接
微信公众号